Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland.

@article{Aaltonen2017DrugSO,
  title={Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland.},
  author={Kalle Aaltonen and Jaana Tuulikki Joensuu and Laura Piril{\"a} and Markku J. Kauppi and Toini I Uutela and Tuire Varjolahti-Lehtinen and Timo K Yli-Kerttula and Pia Isom{\"a}ki and Dan C. E. Nordstr{\"o}m and Tuulikki Sokka},
  journal={Scandinavian journal of rheumatology},
  year={2017},
  volume={46 5},
  pages={
          359-363
        }
}
OBJECTIVE A systematic review found that an average of 27% of rheumatoid arthritis (RA) patients using tumour necrosis factor (TNF) inhibitors discontinue their treatment within 1 year. The aim of this study was to assess drug survival on TNF inhibitors among patients with RA. METHODS Patients were identified from the National Register for Biologic Treatment in Finland (ROB-FIN), which is a longitudinal cohort study established to monitor the effectiveness and safety of biologic drugs in… CONTINUE READING
BETA